cas 3934-20-1|| where to buy 2,4-Dichloropyrimidine

Produktname:2,4-Dichloropyrimidine

IUPAC Name:2,4-dichloropyrimidine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM166462-500g	in stock	ƎȬƎ
CM166462-1000g	in stock	ưƀț

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3934-20-1 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:3934-20-1; Molekulare Formel:C4H2Cl2N2; Schmelzpunkt:-; SMILES-Code:ClC1=NC(Cl)=NC=C1; Dichte:

: Katalognummer:CM166462; Molekulargewicht:148.97; Siedepunkt:209.1°C at 760 mmHg; Mdl-Nr.:MFCD00006061; Lagerung:Store in freezer, under -20°C.

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Momelotinib; GSK’s novel small molecule drug, Momelotinib (Ojjaara) has been approved by the U.S. FDA on September 15 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
Myelofibrosis is a rare and fatal form of bone marrow cancer, often resulting in anemia, constitutional symptoms such as fatigue, night sweats, and bone pain, and splenomegaly. These key manifestations of myelofibrosis, including anaemia, have limited treatment options and causing over 30% patients discontinuing treatment.
Momelotinib fills a significant unmet medical need, and has a potential of being a standard-of-care treatment for newly diagnosed and previously treated patients with anaemia. Under a unique mechanism of action, Momelotinib, inhibits Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1) along three key signalling pathways. The phase III study has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly.

: Brepocitinib; Priovant Therapeutics announced positive Phase 2 NEPTUNE study results for brepocitinib in Non-Infectious Uveitis (NIU), showing strongest efficacy data in NIU observed to date. Brepocitinib selectively binds to and inhibits the activation of TYK2 and JAK1, thereby disrupting TYK2 and JAK-1-dependent cytokine signaling. This may reduce inflammatory responses and prevent inflammation-induced damage caused by certain immunological diseases.